Biology and clinical management of prostate cancer bone metastasis

Frontiers in Bioscience

Volumn 12, Issue 9, 2007, Pages 3273-3286

  Ye, Xiang Cang ^a   Choueiri, Michel ^a   Tu, Shi Ming ^a   Lin, Sue Hwa ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Androgen deprivation therapy; Bone; Cancer stem cell; Metastasis; Osteoblast; Prostate cancer; PSA

Indexed keywords

BONE TUMOR; HUMAN; MALE; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR; REVIEW;

BONE NEOPLASMS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 34347231279     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2311     Document Type: Article

References (156)

1. American Cancer Society: Cancer Facts and Figures 2006. in American Cancer Society, Atlanta, Ga, (2006)
2. S. M. Tu and S. H. Lin: Clinical aspects of bone metastases in prostate cancer. Cancer Treat Res 118, 23-46 (2004)
3. E. L. Paquette, L. Sun, L. R. Paquette, R. Connelly, D. G. McLeod and J. W. Moul: Improved prostate cancerspecific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 60, 756-9 (2002) (Pubitemid 35300331)
4. L. Bubendorf, A. Schopfer, U. Wagner, G. Sauter, H. Moch, N. Willi, T. C. Gasser and M. J. Mihatsch: Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum Pathol 31, 578-83 (2000) (Pubitemid 30323983)
5. R. B. Shah, R. Mehra, A. M. Chinnaiyan, R. Shen, D. Ghosh, M. Zhou, G. R. Macvicar, S. Varambally, J. Harwood, T. A. Bismar, R. Kim, M. A. Rubin and K. J. Pienta: Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64, 9209-16 (2004) (Pubitemid 39665537)
6. O. Smaletz, H. I. Scher, E. J. Small, D. A. Verbel, A. McMillan, K. Regan, W. K. Kelly and M. W. Kattan: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20, 3972-82 (2002)
7. J. Ewing: Neoplastic Diseases, Phiadelphia, (1928)
8. O. V. Batson: The function of the vertebral veins and their role in the spread of metastases. 1940. Clin Orthop Relat Res, 4-9 (1995)
9. M. P. Roudier, L. D. True, C. S. Higano, H. Vesselle, W. Ellis, P. Lange and R. L. Vessella: Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34, 646-53 (2003) (Pubitemid 36875509)
10. A. Berruti, L. Dogliotti, R. Bitossi, G. Fasolis, G. Gorzegno, M. Bellina, M. Torta, F. Porpiglia, D. Fontana and A. Angeli: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164, 1248-53 (2000)
11. F. Arguello, R. B. Baggs, R. E. Duerst, L. Johnstone, K. McQueen and C. N. Frantz: Pathogenesis of vertebral metastasis and epidural spinal cord compression. Cancer 65, 98-106 (1990) (Pubitemid 20026818)
12. B. Desoize, S. Amico, H. Larbre, P. Coninx and J. C. Jardillier: Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma. Clin Biochem 24, 443-6 (1991)
13. J. M. Wolff, T. Ittel, W. Boeckmann, T. Reinike, F. K. Habib and G. Jakse: Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer. Eur Urol 30, 302-6 (1996) (Pubitemid 26362870)
14. T. Kylmala, T. L. Tammela, L. Risteli, J. Risteli, M. Kontturi and I. Elomaa: Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 71, 1061-4 (1995)
15. T. Tamada, T. Sone, T. Tomomitsu, Y. Jo, H. Tanaka and M. Fukunaga: Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 19, 45-51 (2001) (Pubitemid 32048197)
16. D. A. Hanson, M. A. Weis, A. M. Bollen, S. L. Maslan, F. R. Singer and D. R. Eyre: A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7, 1251-8 (1992) (Pubitemid 23000964)
17. S. Paget: The distribution of secondary growths in cancer of the breast. Lancet 1, 571-573 (1889)
18. I. J. Fidler: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3, 453-8 (2003) (Pubitemid 37328849)
19. K. Tantivejkul, L. M. Kalikin and K. J. Pienta: Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 91, 706-17 (2004)
20. M. V. Seiden, P. W. Kantoff, K. Krithivas, K. Propert, M. Bryant, E. Haltom, L. Gaynes, I. Kaplan, G. Bubley and W. DeWolf: Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 12, 2634-9 (1994) (Pubitemid 24379650)
21. E. Corey, E. W. Arfman, M. M. Oswin, S. W. Melchior, D. J. Tindall, C. Y. Young, W. J. Ellis and R. L. Vessella: Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology 50, 184-8 (1997) (Pubitemid 27339930)
22. R. Oberneder, R. Riesenberg, M. Kriegmair, U. Bitzer, R. Klammert, P. Schneede, A. Hofstetter, G. Riethmuller and K. Pantel: Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer. Urol Res 22, 3-8 (1994) (Pubitemid 24149213)
23. K. Pantel, C. Aignherr, J. Kollermann, J. Caprano, G. Riethmuller and M. W. Kollermann: Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. Eur J Cancer 31A, 1627-32 (1995)
24. A. Zippelius, P. Kufer, G. Honold, M. W. Kollermann, R. Oberneder, G. Schlimok, G. Riethmuller and K. Pantel: Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 15, 2701-8 (1997) (Pubitemid 27289903)
25. P. Albers, Y. Ko, E. Wardelmann, D. Schmidt, M. Adam, H. Vetter and S. C. Muller: Limitations of detection of bone-marrow micrometastasis in prostate carcinoma patients by CK18/PSA immunocytochemistry and PSA RT-PCR. Anticancer Res 20, 2107-11 (2000) (Pubitemid 30636192)
26. W. J. Ellis, R. L. Vessella, E. Corey, E. W. Arfman, M. M. Oswin, S. Melchior and P. H. Lange: The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J Urol 159, 1134-8 (1998) (Pubitemid 28172779)
27. C. L. Gao, S. Maheshwari, R. C. Dean, L. Tatum, R. Mooneyhan, R. R. Connelly, D. G. McLeod, S. Srivastava and J. W. Moul: Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer. Urology 53, 714-21 (1999) (Pubitemid 29163035)
28. R. Millon, D. Jacqmin, D. Muller, J. Guillot, M. Eber and J. Abecassis: Detection of prostate-specific antigen-or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications. Eur Urol 36, 278-85 (1999) (Pubitemid 29419442)
29. S. F. Shariat, M. W. Kattan, W. Song, D. Bernard, E. Gottenger, T. M. Wheeler and K. M. Slawin: Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res 63, 5874-8 (2003) (Pubitemid 37187487)
30. J. E. Lehr and K. J. Pienta: Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 90, 118-23 (1998) (Pubitemid 28114412)
31. R. A. Sikes, B. E. Nicholson, K. S. Koeneman, N. M. Edlund, E. A. Bissonette, M. J. Bradley, G. N. Thalmann, M. G. Cecchini, K. J. Pienta and L. W. Chung: Cellular interactions in the tropism of prostate cancer to bone. Int J Cancer 110, 497-503 (2004) (Pubitemid 38658014)
32. C. R. Cooper, C. H. Chay and K. J. Pienta: The role of alpha (v) beta (3) in prostate cancer progression. Neoplasia 4, 191-4 (2002) (Pubitemid 34525250)
33. C. L. Hall, J. Dai, K. L. van Golen, E. T. Keller and M. W. Long: Type I Collagen Receptor ({alpha}2{beta}1) Signaling Promotes the Growth of Human Prostate Cancer Cells within the Bone. Cancer Res 66, 8648-54 (2006) (Pubitemid 44449180)
34. E. Putz, K. Witter, S. Offner, P. Stosiek, A. Zippelius, J. Johnson, R. Zahn, G. Riethmuller and K. Pantel: Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 59, 241-8 (1999) (Pubitemid 29062984)
35. D. Q. Zheng, A. S. Woodard, G. Tallini and L. R. Languino: Substrate specificity of alpha (v) beta (3) integrinmediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. J Biol Chem 275, 24565-74 (2000) (Pubitemid 30626553)
36. Y. X. Sun, M. Fang, J. Wang, C. R. Cooper, K. J. Pienta and R. S. Taichman: Expression and activation of alpha (v) beta (3) integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate (2006)
37. R. S. Taichman, C. Cooper, E. T. Keller, K. J. Pienta, N. S. Taichman and L. K. McCauley: Use of the stromal cellderived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62, 1832-7 (2002) (Pubitemid 34408510)
38. Y. X. Sun, J. Wang, C. E. Shelburne, D. E. Lopatin, A. M. Chinnaiyan, M. A. Rubin, K. J. Pienta and R. S. Taichman: Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89, 462-73 (2003) (Pubitemid 36648768)
39. A. Miyauchi, J. Alvarez, E. M. Greenfield, A. Teti, M. Grano, S. Colucci, A. Zambonin-Zallone, F. P. Ross, S. L. Teitelbaum, D. Cheresh and K. A. Hruska: Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem 266, 20369-74 (1991) (Pubitemid 21908468)
40. A. Elgavish, C. Prince, P. L. Chang, K. Lloyd, R. Lindsey and R. Reed: Osteopontin stimulates a subpopulation of quiescent human prostate epithelial cells with high proliferative potential to divide in vitro. Prostate 35, 83-94 (1998) (Pubitemid 28183290)
41. A. Angelucci, C. Festuccia, G. D'Andrea, A. Teti and M. Bologna: Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biol Chem 383, 229-34 (2002) (Pubitemid 34224046)
42. T. Standal, M. Borset and A. Sundan: Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26, 179-84 (2004)
43. D. Coppola, M. Szabo, D. Boulware, P. Muraca, M. Alsarraj, A. F. Chambers and T. J. Yeatman: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10, 184-90 (2004) (Pubitemid 38114178)
44. A. C. Khodavirdi, Z. Song, S. Yang, C. Zhong, S. Wang, H. Wu, C. Pritchard, P. S. Nelson and P. Roy-Burman: Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 66, 883-8 (2006) (Pubitemid 43165954)
45. S. De, J. Chen, N. V. Narizhneva, W. Heston, J. Brainard, E. H. Sage and T. V. Byzova: Molecular pathway for cancer metastasis to bone. J Biol Chem 278, 39044-50 (2003) (Pubitemid 37221807)
46. K. Jacob, M. Webber, D. Benayahu and H. K. Kleinman: Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res 59, 4453-7 (1999) (Pubitemid 29418768)
47. Q. Shi, S. Bao, J. A. Maxwell, E. D. Reese, H. S. Friedman, D. D. Bigner, X. F. Wang and J. N. Rich: Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem 279, 52200-9 (2004) (Pubitemid 39656594)
48. C. J. Logothetis and S. H. Lin: Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5, 21-8 (2005) (Pubitemid 40052322)
49. S. C. Jacobs: Spread of prostatic cancer to bone. Urology 21, 337-44 (1983) (Pubitemid 13161851)
50. H. Yonou, A. Ochiai, M. Goya, N. Kanomata, S. Hokama, M. Morozumi, K. Sugaya, T. Hatano and Y. Ogawa: Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate 58, 406-13 (2004) (Pubitemid 38295034)
51. S. Miwa, A. Mizokami, E. T. Keller, R. Taichman, J. Zhang and M. Namiki: The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res 65, 8818-25 (2005) (Pubitemid 41377370)
52. Y. Takuwa, T. Masaki and K. Yamashita: The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun 170, 998-1005 (1990) (Pubitemid 20273366)
53. T. A. Guise, J. J. Yin and K. S. Mohammad: Role of endothelin-1 in osteoblastic bone metastases. Cancer 97, 779-84 (2003) (Pubitemid 36131076)
54. J. B. Nelson, S. P. Hedican, D. J. George, A. H. Reddi, S. Piantadosi, M. A. Eisenberger and J. W. Simons: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1, 944-9 (1995)
55. J. B. Nelson, A. A. Nabulsi, N. J. Vogelzang, J. Breul, B. A. Zonnenberg, D. D. Daliani, C. C. Schulman and M. A. Carducci: Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169, 1143-9 (2003) (Pubitemid 36188190)
56. K. Fizazi, J. Yang, S. Peleg, C. R. Sikes, E. L. Kreimann, D. Daliani, M. Olive, K. A. Raymond, T. J. Janus, C. J. Logothetis, G. Karsenty and N. M. Navone: Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9, 2587-97 (2003) (Pubitemid 36842101)
57. C. Festuccia, D. Giunciuglio, F. Guerra, I. Villanova, A. Angelucci, P. Manduca, A. Teti, A. Albini and M. Bologna: Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion. Oncol Res 11, 17-31 (1999)
58. G. D. Roodman: Mechanisms of bone metastasis. N Engl J Med 350, 1655-64 (2004)
59. D. H. Jones, T. Nakashima, O. H. Sanchez, I. Kozieradzki, S. V. Komarova, I. Sarosi, S. Morony, E. Rubin, R. Sarao, C. V. Hojilla, V. Komnenovic, Y. Y. Kong, M. Schreiber, S. J. Dixon, S. M. Sims, R. Khokha, T. Wada and J. M. Penninger: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-6 (2006)
60. A. Schneider, L. M. Kalikin, A. C. Mattos, E. T. Keller, M. J. Allen, K. J. Pienta and L. K. McCauley: Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146, 1727-36 (2005) (Pubitemid 40396881)
61. K. S. Koeneman, F. Yeung and L. W. Chung: Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39, 246-61 (1999) (Pubitemid 29244499)
62. G. N. Thalmann, P. E. Anezinis, S. M. Chang, H. E. Zhau, E. E. Kim, V. L. Hopwood, S. Pathak, A. C. von Eschenbach and L. W. Chung: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54, 2577-81 (1994) (Pubitemid 24173741)
63. T. T. Wu, R. A. Sikes, Q. Cui, G. N. Thalmann, C. Kao, C. F. Murphy, H. Yang, H. E. Zhau, G. Balian and L. W. Chung: Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostatespecific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 77, 887-94 (1998) (Pubitemid 28378138)
64. D. L. Lin, C. P. Tarnowski, J. Zhang, J. Dai, E. Rohn, A. H. Patel, M. D. Morris and E. T. Keller: Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47, 212-21 (2001) (Pubitemid 32378373)
65. J. M. Brown, E. Corey, Z. D. Lee, L. D. True, T. J. Yun, M. Tondravi and R. L. Vessella: Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57, 611-6 (2001)
66. W. C. Huang, Z. Xie, H. Konaka, J. Sodek, H. E. Zhau and L. W. Chung: Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 65, 2303-13 (2005) (Pubitemid 40490140)
67. W. C. Huang, D. Wu, Z. Xie, H. E. Zhau, T. Nomura, M. Zayzafoon, J. Pohl, C. L. Hsieh, M. N. Weitzmann, M. C. Farach-Carson and L. W. Chung: beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res 66, 9108-16 (2006) (Pubitemid 44521130)
68. M. Zayzafoon, S. A. Abdulkadir and J. M. McDonald: Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem 279, 3662-70 (2004) (Pubitemid 38140608)
69. J. Kawakami, J. E. Cowan, E. P. Elkin, D. M. Latini, J. DuChane and P. R. Carroll: Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Cancer 106, 1708-14 (2006)
70. M. E. Taplin, B. Rajeshkumar, S. Halabi, C. P. Werner, B. A. Woda, J. Picus, W. Stadler, D. F. Hayes, P. W. Kantoff, N. J. Vogelzang and E. J. Small: Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21, 2673-8 (2003) (Pubitemid 46606310)
71. J. Holzbeierlein, P. Lal, E. LaTulippe, A. Smith, J. Satagopan, L. Zhang, C. Ryan, S. Smith, H. Scher, P. Scardino, V. Reuter and W. L. Gerald: Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164, 217-27 (2004) (Pubitemid 38364606)
72. M. Stanbrough, G. J. Bubley, K. Ross, T. R. Golub, M. A. Rubin, T. M. Penning, P. G. Febbo and S. P. Balk: Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66, 2815-25 (2006)
73. D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon and C. Ohlsson: Androgens and bone. Endocr Rev 25, 389-425 (2004) (Pubitemid 38786452)
74. A. Turner, T. C. Chen, T. W. Barber, A. O. Malabanan, M. F. Holick and V. Tangpricha: Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects. Clin Endocrinol (Oxf) 61, 560-6 (2004) (Pubitemid 39545171)
75. A. G. Ruetsche, R. Kneubuehl, M. H. Birkhaeuser and K. Lippuner: Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study. Osteoporos Int 16, 791-8 (2005) (Pubitemid 40933595)
76. F. Yap, W. Hogler, J. Briody, B. Moore, R. Howman-Giles and C. T. Cowell: The skeletal phenotype of men with previous constitutional delay of puberty. J Clin Endocrinol Metab 89, 4306-11 (2004) (Pubitemid 39244430)
77. R. Marcus, D. Leary, D. L. Schneider, E. Shane, M. Favus and C. A. Quigley: The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome. J Clin Endocrinol Metab 85, 1032-7 (2000) (Pubitemid 32269345)
78. L. Vandenput, J. V. Swinnen, S. Boonen, E. Van Herck, R. G. Erben, R. Bouillon and D. Vanderschueren: Role of the androgen receptor in skeletal homeostasis: the androgen-resistant testicular feminized male mouse model. J Bone Miner Res 19, 1462-70 (2004) (Pubitemid 41094347)
79. S. Moverare, K. Venken, A. L. Eriksson, N. Andersson, S. Skrtic, J. Wergedal, S. Mohan, P. Salmon, R. Bouillon, J. A. Gustafsson, D. Vanderschueren and C. Ohlsson: Differential effects on bone of estrogen receptor alpha and androgen receptor activation in orchidectomized adult male mice. Proc Natl Acad Sci U S A 100, 13573-8 (2003) (Pubitemid 37448563)
80. T. Sato, H. Kawano and S. Kato: Study of androgen action in bone by analysis of androgen-receptor deficient mice. J Bone Miner Metab 20, 326-30 (2002) (Pubitemid 40645653)
81. B. C. van der Eerden, N. P. van Til, A. O. Brinkmann, C. W. Lowik, J. M. Wit and M. Karperien: Gender differences in expression of androgen receptor in tibial growth plate and metaphyseal bone of the rat. Bone 30, 891-6 (2002) (Pubitemid 34616019)
82. H. Kawano, T. Sato, T. Yamada, T. Matsumoto, K. Sekine, T. Watanabe, T. Nakamura, T. Fukuda, K. Yoshimura, T. Yoshizawa, K. Aihara, Y. Yamamoto, Y. Nakamichi, D. Metzger, P. Chambon, K. Nakamura, H. Kawaguchi and S. Kato: Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A 100, 9416-21 (2003) (Pubitemid 37033943)
83. S. Yeh, M. Y. Tsai, Q. Xu, X. M. Mu, H. Lardy, K. E. Huang, H. Lin, S. D. Yeh, S. Altuwaijri, X. Zhou, L. Xing, B. F. Boyce, M. C. Hung, S. Zhang, L. Gan and C. Chang: Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A 99, 13498-503 (2002) (Pubitemid 35215410)
84. K. M. Wiren, X. W. Zhang, A. R. Toombs, V. Kasparcova, M. A. Gentile, S. Harada and K. J. Jepsen: Targeted overexpression of androgen receptor in osteoblasts: unexpected complex bone phenotype in growing animals. Endocrinology 145, 3507-22 (2004) (Pubitemid 38830023)
85. S. Kousteni, J. R. Chen, T. Bellido, L. Han, A. A. Ali, C. A. O'Brien, L. Plotkin, Q. Fu, A. T. Mancino, Y. Wen, A. M. Vertino, C. C. Powers, S. A. Stewart, R. Ebert, A. M. Parfitt, R. S. Weinstein, R. L. Jilka and S. C. Manolagas: Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298, 843-6 (2002) (Pubitemid 35231540)
86. H. Y. Kang, C. L. Cho, K. L. Huang, J. C. Wang, Y. C. Hu, H. K. Lin, C. Chang and K. E. Huang: Nongenomic androgen activation of phosphatidylinositol 3-kinase/Akt signaling pathway in MC3T3-E1 osteoblasts. J Bone Miner Res 19, 1181-90 (2004) (Pubitemid 41110571)
87. H. Michael, P. L. Harkonen, H. K. Vaananen and T. A. Hentunen: Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 20, 2224-32 (2005) (Pubitemid 41698785)
88. Q. Chen, H. Kaji, M. Kanatani, T. Sugimoto and K. Chihara: Testosterone increases osteoprotegerin mRNA expression in mouse osteoblast cells. Horm Metab Res 36, 674-8 (2004) (Pubitemid 39486966)
89. D. M. Huber, A. C. Bendixen, P. Pathrose, S. Srivastava, K. M. Dienger, N. K. Shevde and J. W. Pike: Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 142, 3800-8 (2001) (Pubitemid 32802650)
90. Q. Chen, H. Kaji, T. Sugimoto and K. Chihara: Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEBS Lett 491, 91-3 (2001) (Pubitemid 32172008)
91. S. C. Manolagas, S. Kousteni and R. L. Jilka: Sex steroids and bone. Recent Prog Horm Res 57, 385-409 (2002)
92. C. L. Smith and B. W. O'Malley: Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25, 45-71 (2004) (Pubitemid 38292038)
93. M. F. Clarke, J. E. Dick, P. B. Dirks, C. J. Eaves, C. H. Jamieson, D. L. Jones, J. Visvader, I. L. Weissman and G. M. Wahl: Cancer Stem Cells-Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Res 66, 9339-44 (2006) (Pubitemid 44623625)
94. S. M. Tu, S. H. Lin and C. J. Logothetis: Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol 3, 508-13 (2002) (Pubitemid 34863672)
95. I. L. Weissman: Stem cells, clonal progenitors, and commitment to the three lymphocyte lineages: T, B, and NK cells. Immunity 1, 529-31 (1994)
96. H. F. English, R. J. Santen and J. T. Isaacs: Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 11, 229-42 (1987) (Pubitemid 18004762)
97. G. S. Evans and J. A. Chandler: Cell proliferation studies in the rat prostate: II. The effects of castration and androgen-induced regeneration upon basal and secretory cell proliferation. Prostate 11, 339-51 (1987) (Pubitemid 18023662)
98. P. E. Burger, X. Xiong, S. Coetzee, S. N. Salm, D. Moscatelli, K. Goto and E. L. Wilson: Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci U S A 102, 7180-5 (2005) (Pubitemid 40696354)
99. L. Xin, D. A. Lawson and O. N. Witte: The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A 102, 6942-7 (2005) (Pubitemid 40675421)
100. S. Wang, A. J. Garcia, M. Wu, D. A. Lawson, O. N. Witte and H. Wu: Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 103, 1480-5 (2006) (Pubitemid 43191191)
101. T. Reya, S. J. Morrison, M. F. Clarke and I. L. Weissman: Stem cells, cancer, and cancer stem cells. Nature 414, 105-11 (2001) (Pubitemid 33041634)
102. D. Bonnet and J. E. Dick: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3, 730-7 (1997) (Pubitemid 27298715)
103. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison and M. F. Clarke: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100, 3983-8 (2003) (Pubitemid 36418143)
104. H. D. Hemmati, I. Nakano, J. A. Lazareff, M. Masterman-Smith, D. H. Geschwind, M. Bronner-Fraser and H. I. Kornblum: Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100, 15178-83 (2003) (Pubitemid 37518036)
105. S. K. Singh, I. D. Clarke, M. Terasaki, V. E. Bonn, C. Hawkins, J. Squire and P. B. Dirks: Identification of a cancer stem cell in human brain tumors. Cancer Res 63, 5821-8 (2003) (Pubitemid 37187480)
106. A. T. Collins, P. A. Berry, C. Hyde, M. J. Stower and N. J. Maitland: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65, 10946-51 (2005) (Pubitemid 41713363)
107. E. Palmer, B. Henrikson, K. McKusick, H. W. Strauss and F. Hochberg: Pain as an indicator of bone metastasis. Acta Radiol 29, 445-9 (1988)
108. C. Huggins and C. V. Hodges: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168, 9-12 (2002)
109. C. Huggins and C. V. Hodges: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 167, 948-51; discussion 952 (2002)
110. M. Robson and N. Dawson: How is androgendependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am 10, 727-47 (1996) (Pubitemid 26171141)
111. D. A. Loblaw, D. S. Mendelson, J. A. Talcott, K. S. Virgo, M. R. Somerfield, E. Ben-Josef, R. Middleton, H. Porterfield, S. A. Sharp, T. J. Smith, M. E. Taplin, N. J. Vogelzang, J. L. Wade, Jr., C. L. Bennett and H. I. Scher: American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 22, 2927-41 (2004) (Pubitemid 41079913)
112. F. Labrie, A. Dupont, M. Giguere, J. P. Borsanyi, Y. Lacourciere, G. Monfette, J. Emond and N. Bergeron: Benefits of combination therapy with flutamide in patients relapsing after castration. Br J Urol 61, 341-6 (1988)
113. O. Kucuk, E. Fisher, C. M. Moinpour, D. Coleman, M. H. Hussain, A. O. Sartor, G. S. Chatta, B. A. Lowe, M. A. Eisenberger and E. D. Crawford: Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235) Urology 58, 53-8 (2001) (Pubitemid 32633935)
114. W. Kassouf, S. Tanguay and A. G. Aprikian: Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 169, 1742-4 (2003) (Pubitemid 36443485)
115. T. Eichenberger, J. Trachtenberg, P. Toor and A. Keating: Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. J Urol 141, 190-1 (1989) (Pubitemid 19028867)
116. E. J. Small, A. D. Baron, L. Fippin and D. Apodaca: Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157, 1204-7 (1997) (Pubitemid 27130781)
117. P. W. Kantoff, S. Halabi, M. Conaway, J. Picus, J. Kirshner, V. Hars, D. Trump, E. P. Winer and N. J. Vogelzang: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17, 2506-13 (1999) (Pubitemid 29368252)
118. M. Fakih, C. S. Johnson and D. L. Trump: Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 60, 553-61 (2002) (Pubitemid 35246431)
119. D. P. Byar: Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32, 1126-30 (1973)
120. B. Waymont, T. H. Lynch, J. A. Dunn, L. A. Emtage, D. G. Arkell, D. M. Wallace and G. R. Blackledge: Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol 69, 614-20 (1992)
121. H. J. de Voogt, P. H. Smith, M. Pavone-Macaluso, M. de Pauw and S. Suciu: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 135, 303-7 (1986) (Pubitemid 16131365)
122. L. L. Beynon and G. D. Chisholm: The stable state is not an objective response in hormone-escaped carcinoma of prostate. Br J Urol 56, 702-5 (1984) (Pubitemid 15187559)
123. C. D. Chen, D. S. Welsbie, C. Tran, S. H. Baek, R. Chen, R. Vessella, M. G. Rosenfeld and C. L. Sawyers: Molecular determinants of resistance to antiandrogen therapy. Nat Med 10, 33-9 (2004) (Pubitemid 38524696)
124. E. D. Crawford, M. A. Eisenberger, D. G. McLeod, J. T. Spaulding, R. Benson, F. A. Dorr, B. A. Blumenstein, M. A. Davis and P. J. Goodman: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321, 419-24 (1989) (Pubitemid 19211484)
125. M. A. Eisenberger, B. A. Blumenstein, E. D. Crawford, G. Miller, D. G. McLeod, P. J. Loehrer, G. Wilding, K. Sears, D. J. Culkin, I. M. Thompson, Jr., A. J. Bueschen and B. A. Lowe: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339, 1036-42 (1998) (Pubitemid 28457865)
126. W. Berry, S. Dakhil, M. Modiano, M. Gregurich and L. Asmar: Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168, 2439-43 (2002) (Pubitemid 35402635)
127. I. F. Tannock, R. de Wit, W. R. Berry, J. Horti, A. Pluzanska, K. N. Chi, S. Oudard, C. Theodore, N. D. James, I. Turesson, M. A. Rosenthal and M. A. Eisenberger: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351, 1502-12 (2004) (Pubitemid 39315317)
128. D. P. Petrylak, C. M. Tangen, M. H. Hussain, P. N. Lara, Jr., J. A. Jones, M. E. Taplin, P. A. Burch, D. Berry, C. Moinpour, M. Kohli, M. C. Benson, E. J. Small, D. Raghavan and E. D. Crawford: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351, 1513-20 (2004) (Pubitemid 39315318)
129. A. K. Lee and S. J. Frank: Update on radiation therapy in prostate cancer. Hematol Oncol Clin North Am 20, 857-78 (2006) (Pubitemid 44067399)
130. T. M. Pisansky: External-beam radiotherapy for localized prostate cancer. N Engl J Med 355, 1583-91 (2006) (Pubitemid 44547809)
131. A. N. Serafini, S. J. Houston, I. Resche, D. P. Quick, F. M. Grund, P. J. Ell, A. Bertrand, F. R. Ahmann, E. Orihuela, R. H. Reid, R. A. Lerski, B. D. Collier, J. H. McKillop, G. L. Purnell, A. P. Pecking, F. D. Thomas and K. A.
132. O. Sartor, R. H. Reid, P. J. Hoskin, D. P. Quick, P. J. Ell, R. E. Coleman, J. A. Kotler, L. M. Freeman and P. Olivier: Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormonerefractory prostate cancer. Urology 63, 940-5 (2004) (Pubitemid 38596683)
133. A. T. Porter, A. J. McEwan, J. E. Powe, R. Reid, D. G. McGowan, H. Lukka, J. R. Sathyanarayana, V. N. Yakemchuk, G. M. Thomas and L. E. Erlich: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25, 805-13 (1993) (Pubitemid 23123384)
134. H. Palmedo, A. Manka-Waluch, P. Albers, I. G. Schmidt-Wolf, M. Reinhardt, S. Ezziddin, A. Joe, R. Roedel, R. Fimmers, F. F. Knapp, Jr., S. Guhlke and H. J. Biersack: Repeated bone-targeted therapy for hormonerefractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21, 2869-75 (2003) (Pubitemid 46621835)
135. S. M. Tu, R. E. Millikan, B. Mengistu, E. S. Delpassand, R. J. Amato, L. C. Pagliaro, D. Daliani, C. N. Papandreou, T. L. Smith, J. Kim, D. A. Podoloff and C. J. Logothetis: Bone-targeted therapy for advanced androgenindependent carcinoma of the prostate: a randomised phase II trial. Lancet 357, 336-41 (2001) (Pubitemid 32128538)
136. N. Kohno, K. Aogi, H. Minami, S. Nakamura, T. Asaga, Y. Iino, T. Watanabe, C. Goessl, Y. Ohashi and S. Takashima: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23, 3314-21 (2005)
137. J. M. Bruder, J. Z. Ma, J. W. Basler and M. D. Welch: Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 67, 152-5 (2006) (Pubitemid 43069275)
138. V. B. Shahinian, Y. F. Kuo, J. L. Freeman and J. S. Goodwin: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352, 154-64 (2005) (Pubitemid 40096612)
139. T. J. Polascik, R. W. Given, C. Metzger, S. R. Julian, J. C. Vestal, G. S. Karlin, C. S. Barkley, D. L. Bilhartz, L. T. McWhorter and L. V. Lacerna: Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 66, 1054-9 (2005) (Pubitemid 41587160)
140. F. Saad: Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 1, 145-52 (2002) (Pubitemid 37012395)
141. F. Saad, D. M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J. L. Chin, J. J. Vinholes, J. A. Goas and M. Zheng: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96, 879-82 (2004) (Pubitemid 38807610)
142. F. Saad, D. M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J. L. Chin, J. J. Vinholes, J. A. Goas and B. Chen: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94, 1458-68 (2002)
143. E. J. Small, M. R. Smith, J. J. Seaman, S. Petrone and M. O. Kowalski: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21, 4277-84 (2003) (Pubitemid 46621802)
144. D. S. Ernst, I. F. Tannock, E. W. Winquist, P. M. Venner, L. Reyno, M. J. Moore, K. Chi, K. Ding, C. Elliott and W. Parulekar: Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21, 3335-42 (2003) (Pubitemid 46613484)
145. T. H. Diamond, C. S. Higano, M. R. Smith, T. A. Guise and F. R. Singer: Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100, 892-9 (2004) (Pubitemid 38222847)
146. A. J. Armstrong and M. A. Carducci: New drugs in prostate cancer. Curr Opin Urol 16, 138-45 (2006) (Pubitemid 43791781)
147. N. A. Dawson: New molecular targets in advanced prostate cancer. Expert Rev Anticancer Ther 6, 993-1002 (2006) (Pubitemid 44203378)
148. T. A. Guise and K. S. Mohammad: Endothelins in bone cancer metastases. Cancer Treat Res 118, 197-212 (2004)
149. M. A. Carducci, R. J. Padley, J. Breul, N. J. Vogelzang, B. A. Zonnenberg, D. D. Daliani, C. C. Schulman, A. A. Nabulsi, R. A. Humerickhouse, M. A. Weinberg, J. L. Schmitt and J. B. Nelson: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21, 679-89 (2003) (Pubitemid 46621903)
150. D. L. Livant, R. K. Brabec, K. J. Pienta, D. L. Allen, K. Kurachi, S. Markwart and A. Upadhyaya: Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 60, 309-20 (2000) (Pubitemid 30070757)
151. S. Zucker, J. Cao and W. T. Chen: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642-50 (2000) (Pubitemid 32197703)
152. P. A. Burch, G. A. Croghan, D. A. Gastineau, L. A. Jones, J. S. Kaur, J. W. Kylstra, R. L. Richardson, F. H. Valone and S. Vuk-Pavlovic: Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 60, 197-204 (2004) (Pubitemid 38971831)
153. J. W. Simons and N. Sacks: Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 24, 419-24 (2006) (Pubitemid 44311548)
154. G. Liu, G. Wilding, M. J. Staab, D. Horvath, K. Miller, A. Dresen, D. Alberti, R. Arzoomanian, R. Chappell and H. H. Bailey: Phase II study of 1alpha-hydroxyvitamin D (2) in the treatment of advanced androgen-independent prostate cancer. Clin Cancer Res 9, 4077-83 (2003) (Pubitemid 37204023)
155. M. A. Carducci, J. Gilbert, M. K. Bowling, D. Noe, M. A. Eisenberger, V. Sinibaldi, Y. Zabelina, T. L. Chen, L. B. Grochow and R. C. Donehower: A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7, 3047-55 (2001) (Pubitemid 32963823)
156. Y. Huang, Q. He, M. J. Hillman, R. Rong and M. S. Sheikh: Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res 61, 6918-24 (2001) (Pubitemid 32896519)